ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,239Medicare Part D Prescriptions Filled, Including Refills

Rank: 279 out of 1844

$568K Total Retail Price of All Prescriptions

Rank: 265 out of 1844

346 Patients Receiving at Least One Drug in Part D
80%Patients 65 Years and Older
54% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Indiana
Lower avg

Schedule Two
Controlled Substances

6% of this provider’s 346 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

19% of this provider’s 346 patients filled at least one prescription for a schedule three drug, compared to an average of 15%.

Risky Drugs to Seniors

1% of this provider’s 7,162 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

25% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$62 was the average price of a prescription from this provider, compared to $60 among peers.

Prescriptions per Patient

27 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Indiana
LEVOTHYROXINE SODIUM 397 314 1 1
LISINOPRIL 354 271 2 4
HYDROCODONE-ACETAMINOPHEN 314 231 S3 3 2
AMLODIPINE BESYLATE 246 213 4 6
SIMVASTATIN 242 230 5 3
ATORVASTATIN CALCIUM 220 168 6 12
METOPROLOL TARTRATE 184 154 7 11
HYDROCHLOROTHIAZIDE 170 124 8 9
OMEPRAZOLE 168 132 9 5
FENOFIBRATE 155 117 10 71
CITALOPRAM HBR 147 114 11 19
TRAMADOL HCL 141 105 12 18
METFORMIN HCL 134 90 13 8
FUROSEMIDE 132 109 14 7
WARFARIN SODIUM 124 93 15 13
PRAVASTATIN SODIUM 124 114 15 10
BENAZEPRIL HCL 123 93 17 75
POTASSIUM CHLORIDE 119 86 18 16
CARVEDILOL 118 98 19 22
ATENOLOL 112 96 20 17
DONEPEZIL HCL 101 101 21 26
LOSARTAN POTASSIUM 96 82 22 24
GABAPENTIN 87 74 23 15
SERTRALINE HCL 81 67 24 21
GLIMEPIRIDE 80 58 25 35
NAMENDA 78 76 26 33
METOPROLOL SUCCINATE 71 65 27 14
PANTOPRAZOLE SODIUM 66 65 28 32
CRESTOR 65 58 29 30
SPIRIVA 62 50 30 57
ISOSORBIDE MONONITRATE ER 62 54 30 59
CLONIDINE HCL 61 48 32 64
METFORMIN HCL ER 61 36 32 46
ZETIA 60 34 34 81
KLOR-CON M20 60 50 34 54
ESCITALOPRAM OXALATE 58 46 36 52
CYMBALTA 58 57 36 36
DIOVAN 57 54 38 58
TRICOR 56 55 39 109
MELOXICAM 56 36 39 28
LIPITOR 54 41 41 159
PLAVIX 52 44 42 61
ADVAIR DISKUS 52 28 42 51
LOSARTAN-HYDROCHLOROTHIAZIDE 52 52 42 47
TAMSULOSIN HCL 51 37 45 27
DILTIAZEM HCL 50 40 46 221
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Jan. 21, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.